News Archive
|
16 May. 2018 BIA Separations and Biomay collaborate on production and purification of large DNA plasmidsCollaboration enables high yield, high purity supercoiled plasmid DNA manufacture for therapeutic application [more] |
|
6 Dec. 2016 Biomay Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation AwardBiomay announces that the company has been named one of the winners of the Corporate LiveWire 2016 Healthcare and Life Sciences Awards in the category Best in Allergy Therapeutics Developments. "We are delighted that our...[more] |
|
3 Sep. 2015 Fresenius Medical Care releases new adsorber IgEnio® in Europe for treatment of severe allergic symptomsFresenius Medical Care has released a new single-use adsorber for the treatment of IgE (ImmunoglobulinE)-mediated diseases in the European market. Latest epidemiological data shows that IgE-mediated diseases affect more than 25...[more] |
|
4 Sep. 2014 Biomay AG completes capital increase in the amount of €2.8 million from existing investorsBiomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding...[more] |
|
19 Sep. 2013 Biomay completes private placement and receives ERP loanBiomay announced today that the company has completed a private placement with a volume of 3 million Euros. The new shares were subscribed by the group of existing shareholders. In Addition, the company has been awarded a...[more] |
|
14 Sep. 2012 Biomay Extends GMP Manufacturing Authorization for Phase III and IV BiologicalsBiomay announces the successful extension of its manufacturing authorization for biologicals for all clinical phases and for market supply. The respective authorization and certificate of GMP compliance were granted recently to...[more] |
|
20 Jan. 2011 Biomay Appoints Rainer Henning as Chief Executive OfficerBiomay announces the appointment of Dr. Rainer Henning as new Chief Executive Officer.[more] |
|
2 Nov. 2010 Development of Biomay´s BM32 vaccine for grass pollen allergy progressing according to planBiomay announces that the development programme of BM32 – a new vaccine for immunotherapy of grass pollen allergy – is progressing well and according to plan.[more] |
|
20 Jan. 2010 New Aliquot Sizes and Prices of Research-grade Recombinant AllergensBiomay wishes to inform its customers about a few changes in the distribution of its research-grade recombinant allergens.[more] |
|
27 Jul. 2009 Biomay and RBPS-Technologies Sign Agreement for GMP Minicircle DNABiomay and RBPS-Technologies announce their manufacturing cooperation for production of GMP-grade minicircle DNA.[more] |
Biomay AG completes capital increase in the amount of €2.8 million from existing investors
Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. www.biomay.com